Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST
- PMID: 15483011
- DOI: 10.1200/JCO.2004.07.960
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST
Comment on
-
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.J Clin Oncol. 2004 Nov 15;22(22):4456-62. doi: 10.1200/JCO.2004.01.185. Epub 2004 Oct 13. J Clin Oncol. 2004. PMID: 15483017 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
